Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene
delivery failed to show efficacy. Major challenges include the need to precisely control in …

A number of vascular therapies could benefit from advanced methods for presentation of
angiogenic growth factors, including growth of endothelium on small caliber vascular grafts …

Although vascular endothelial growth factor (VEGF) has been described as a potent
angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by …

A major challenge for therapeutic delivery of angiogenic agents such as vascular
endothelial growth factor (VEGF) is to achieve sustained, low dose signaling leading to …

Vascular endothelial growth factor (VEGF) is a key factor in endothelial cell biology and
blood vessel formation and a candidate therapeutic for the stimulation of angiogenesis …

Synergy in the downstream signaling pathways of the vascular endothelial growth factor
receptor-2 (VEGFR-2) and the integrin αvβ3 is critical for blood vessel formation. Thus …

Despite major advances in medical, catheter-based or surgical treatment, cardiovascular
diseases such as peripheral artery disease and coronary artery disease still cause …

The modulation of angiogenic processes in matrices is of great interest in tissue
engineering. We assessed the angiogenic effects of fibrin-immobilized VEGF and bFGF in …

Background Therapeutic angiogenesis with vascular endothelial growth factor (VEGF),
delivered either via recombinant protein infusion or via gene therapy, has shown promise in …

We have engineered polymer-based microenvironments that promote vasculogenesis both
in vitro and in vivo through synergistic integrin-growth factor receptor signalling. Poly (ethyl …